Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of Hengli botulinum toxin type A injection for trigeminal neuralgia
CTR20240959Phase 2Active
- Sponsor
- Lanzhou Biotechnology Development
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lanbotulinumtoxin-A in trigeminal neuralgia (TN), sponsored by Lanzhou Biotechnology Development. Started Apr 2024; status: active.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on CTR20240959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240959.